You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTamsulosin
Accession NumberDB00706  (APRD00036)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-1B and alpha-1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in human prostate are of the alpha-1A subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder neck and prostate.

Structure
Thumb
Synonyms
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
Tamsulosin
Tamsulosina
Tamsulosine
Tamsulosinum
External Identifiers
  • LY 253351
  • Y 617
  • YM 12617-1
  • YM-617
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-tamsulosin CRtablet (extended-release)0.4 mgoralAvanstra Inc2011-09-192014-08-21Canada
Flomaxcapsule (sustained-release)0.4 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1998-06-192009-08-27Canada
Flomaxcapsule.4 mg/1oralbryant ranch prepack1997-09-12Not applicableUs
Flomaxcapsule.4 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.1997-09-12Not applicableUs
Flomaxcapsule.4 mg/1oralCardinal Health1997-09-12Not applicableUs
Flomaxcapsule.4 mg/1oralPhysicians Total Care, Inc.2001-08-28Not applicableUs
Flomaxcapsule.4 mg/1oralA S Medication Solutions Llc1999-06-03Not applicableUs
Flomaxcapsule.4 mg/1oralLake Erie Medical DBA Quality Care Products2010-05-13Not applicableUs
Flomaxcapsule.4 mg/1oralREMEDYREPACK INC.2011-03-30Not applicableUs
Flomaxcapsule.4 mg/1oralSTAT Rx USA LLC1997-09-12Not applicableUs
Flomaxcapsule.4 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.1997-09-12Not applicableUs
Flomax CRtablet (extended-release)0.4 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2005-10-11Not applicableCanada
Jamp-tamsulosincapsule (sustained-release)0.4 mgoralJamp Pharma Corporation2010-06-162012-07-05Canada
Mylan-tamsulosincapsule (extended release)0.4 mgoralMylan Pharmaceuticals Ulc2007-08-16Not applicableCanada
Ran-tamsulosincapsule (sustained-release)0.4 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-08-152012-06-13Canada
Ratio-tamsulosincapsule (sustained-release)0.4 mgoralTeva Canada Limited2007-04-27Not applicableCanada
Sandoz Tamsulosincapsule (sustained-release)0.4 mgoralSandoz Canada Incorporated2014-03-19Not applicableCanada
Sandoz Tamsulosincapsule (sustained-release)0.4 mgoralSandoz Canada Incorporated2007-05-16Not applicableCanada
Sandoz Tamsulosin CRtablet (extended-release)0.4 mgoralSandoz Canada Incorporated2011-01-04Not applicableCanada
Tamsulosin CRtablet (extended-release)0.4 mgoralSivem Pharmaceuticals Ulc2014-10-08Not applicableCanada
Tamsulosin CRtablet (extended-release)0.4 mgoralSanis Health Inc2014-07-24Not applicableCanada
Tamsulosin CRtablet (extended-release)0.4 mgoralPro Doc Limitee2013-11-21Not applicableCanada
Teva-tamsulosincapsule (sustained-release)0.4 mgoralTeva Canada Limited2007-02-21Not applicableCanada
Teva-tamsulosin CRtablet (extended-release)0.4 mgoralTeva Canada Limited2013-09-04Not applicableCanada
Uflocapsule (sustained-release)0.4 mgoralTriton Pharma IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tamsulosin CRtablet (extended-release)0.4 mgoralApotex Inc2012-02-09Not applicableCanada
Tamsulosin Hydrochloridecapsule.4 mg/1oralBlenheim Pharmacal, Inc.2013-10-07Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2010-03-02Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralAmerican Health Packaging2014-01-17Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralContract Pharmacy Services Pa2010-07-28Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralSynthon Pharmaceuticals, Inc.2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralClinical Solutions Wholesale, Llc2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralCitron Pharma LLC2013-04-30Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralREMEDYREPACK INC.2014-08-012016-04-05Us
Tamsulosin Hydrochloridecapsule.4 mg/1oralREMEDYREPACK INC.2013-04-22Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralREMEDYREPACK INC.2011-07-20Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralAmerican Health Packaging2010-10-072015-12-29Us
Tamsulosin Hydrochloridecapsule.4 mg/1oralDispensing Solutions, Inc.2010-07-15Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralbryant ranch prepack2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralWockhardt Limited2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralREMEDYREPACK INC.2014-04-09Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralREMEDYREPACK INC.2011-05-18Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralBlenheim Pharmacal, Inc.2013-09-30Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralTeva Pharmaceuticals USA Inc2010-04-272015-12-31Us
Tamsulosin Hydrochloridecapsule.4 mg/1oralMed Vantx, Inc.2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralProficient Rx LP2010-07-15Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralCardinal Health2010-10-07Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralREMEDYREPACK INC.2014-03-172016-04-05Us
Tamsulosin Hydrochloridecapsule.4 mg/1oralAphena Pharma Solutions Tennessee, Llc2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralPar Pharmaceutical2013-03-19Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralMc Kesson Contract Packaging2013-05-10Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralAurobindo Pharma Limited2013-04-30Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralSun Pharmaceutical Industries Limited2010-07-15Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralCardinal Health2010-05-07Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralREMEDYREPACK INC.2013-07-25Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralPd Rx Pharmaceuticals, Inc.2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralMajor Pharmaceuticals2015-01-05Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralCadila Healthcare Limited2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralDIRECT RX2015-11-25Not applicableUs
Tamsulosin Hydrochloridecapsule, gelatin coated.4 mg/1oralCardinal Health2010-05-10Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralREMEDYREPACK INC.2013-07-05Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralRebel Distributors Corp2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralSandoz Inc2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralPreferred Pharmaceuticals, Inc.2014-05-08Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralPhysicians Total Care, Inc.2010-03-10Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralREMEDYREPACK INC.2013-02-272016-04-05Us
Tamsulosin Hydrochloridecapsule.4 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-29Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralUnit Dose Services2010-07-15Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralPreferred Pharmaceuticals, Inc2010-10-07Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralWOCKHARDT USA LLC2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralSt Marys Medical Park Pharmacy2013-05-22Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralAidarex Pharmaceuticals LLC2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralMylan Pharmaceuticals Inc.2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-07-15Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-02-20Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralGolden State Medical Supply, Inc.2013-03-15Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralH.J. Harkins Company, Inc.2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralMylan Institutional Inc.2010-05-07Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralSTAT Rx USA LLC2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralActavis Elizabeth LLC2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralAvera Mc Kennan Hospital2015-03-31Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralCarilion Materials Management2010-07-15Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2010-04-27Not applicableUs
Tamsulosin Hydrochloridecapsule.4 mg/1oralClinical Solutions Wholesale2010-10-07Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetamsalHemofarm
Contiflo XLRanbaxy
FlomaxtraAstellas
Harnal DAstellas
MaxrinSquare
MecirBoehringer Ingelheim
OmexelAstellas
OmiproJelfa
OmixAstellas
OmnicAstellas Pharma Europe
PradifBoehringer Ingelheim
RanomaxRanbaxy
SaloverAversi
SecotexBoehringer Ingelheim
StronazonActavis
TamsactActavis
TamsolApex
TamsulAspen Pharmacare
UrimaxCeleris
Brand mixtures
NameLabellerIngredients
Dutasteride and Tamsulosin HydrochloridePar Pharmaceutical
JalynGlaxo Smith Kline Llc
Salts
Name/CASStructureProperties
Tamsulosin Hydrochloride
ThumbNot applicableDBSALT000978
Categories
UNIIG3P28OML5I
CAS number106133-20-4
WeightAverage: 408.512
Monoisotopic: 408.171892706
Chemical FormulaC20H28N2O5S
InChI KeyInChIKey=DRHKJLXJIQTDTD-OAHLLOKOSA-N
InChI
InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1
IUPAC Name
5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzene-1-sulfonamide
SMILES
CCOC1=CC=CC=C1OCCN[[email protected]](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Amphetamine or derivatives
  • Phenylpropane
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed in the treatment of signs and symptoms of benign prostatic hyperplasia (reduction in urinary obstruction and relief of associated manifestations such as hesitancy, terminal dribbling of urine, interrupted or weak stream...etc.)
PharmacodynamicsTamsulosin, a sulfamoylphenethylamine-derivative alpha-adrenoceptor blocker with enhanced specificity for the alpha-adrenoceptors of the prostate, is commonly used to treat benign prostatic hyperplasia (BPH). The drug is commercially available in a racemic mixture of 2 isomers, and is pharmacologically related to doxazocin, prazosin, and terazosin. However, unlike these drugs, tamsulosin has a higher affinity for the alpha-1A- adrenergic receptors, which are located in vascular smooth muscle. Studies show that tamsulosin has about 12 times greater affinity for alpha-1 adrenergic receptors in the prostate than those in the aorta, which may result in a reduced incidence of adverse cardiovascular effects.
Mechanism of actionTamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. At least three discrete alpha1-adrenoceptor subtypes have been identified: alpha-1A, alpha-1B and alpha-1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1-receptors in human prostate are of the alpha-1A subtype. Blockage of these receptors causes relaxation of smooth muscles in the bladder neck and prostate, and thus decreases urinary outflow resistance in men.
Related Articles
AbsorptionAbsorption of tamsulosin HCI from capsules 0.4 mg is essentially complete (>90%) following oral administration under fasting conditions.
Volume of distribution
  • 16 L [intravenous administration to ten healthy male adults]
Protein binding94%-99%
Metabolism

Tamsulosin HCI is extensively metabolized by cytochrome P450 enzymes in the liver, however, the pharmacokinetic profile of the metabolites in humans has not been established.

Route of eliminationTamsulosin hydrochloride is extensively metabolized by cytochrome P450 enzymes in the liver and less than 10% of the dose is excreted in urine unchanged. The metabolites of tamsulosin hydrochloride undergo extensive conjugation to glucuronide or sulfate prior to renal excretion. On administration of the radiolabeled dose of tamsulosin hydrochloride to four healthy volunteers, 97% of the administered radioactivity was recovered, with urine (76%) representing the primary route of excretion compared to feces (21%) over 168 hours.
Half life5-7 hours
Clearance
  • 2.88 L/h
ToxicityLD50 = 650 mg/kg (in rats)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.997
Blood Brain Barrier+0.5915
Caco-2 permeable-0.6473
P-glycoprotein substrateSubstrate0.5911
P-glycoprotein inhibitor INon-inhibitor0.5734
P-glycoprotein inhibitor IINon-inhibitor0.5522
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6012
CYP450 1A2 substrateNon-inhibitor0.7876
CYP450 2C9 inhibitorInhibitor0.5916
CYP450 2D6 inhibitorNon-inhibitor0.8614
CYP450 2C19 inhibitorNon-inhibitor0.5056
CYP450 3A4 inhibitorInhibitor0.718
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6146
Ames testNon AMES toxic0.6245
CarcinogenicityNon-carcinogens0.6419
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4091 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8367
hERG inhibition (predictor II)Non-inhibitor0.6971
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
  • Impax laboratories inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Synthon pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Wockhardt ltd
  • Zydus pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tablet (extended-release)oral0.4 mg
Capsuleoral
Capsule (immediate and extended release)oral
Capsule (extended release)oral0.4 mg
Capsuleoral.4 mg/1
Capsule, gelatin coatedoral.4 mg/1
Capsule (sustained-release)oral0.4 mg
Prices
Unit descriptionCostUnit
Flomax 0.4 mg capsule4.71USD capsule
Tamsulosin hcl 0.4 mg capsule4.3USD capsule
Flomax Cr 0.4 mg Extended-Release Tablet0.63USD tablet
Mylan-Tamsulosin 0.4 mg Sustained-Release Capsule0.63USD capsule
Novo-Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Ran-Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Ratio-Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Sandoz Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
Tamsulosin 0.4 mg Sustained-Release Capsule0.57USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2144077 No2005-05-242013-09-10Canada
CA2490299 No2008-08-262023-12-24Canada
US4703063 No1993-04-272010-04-27Us
US5565467 No1995-11-202015-11-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point226-228 °C (HCl salt)Not Available
water solubilitySparingly soluble in waterNot Available
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00655 mg/mLALOGPS
logP3.05ALOGPS
logP2.04ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)9.93ChemAxon
pKa (Strongest Basic)9.28ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.88 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity108.86 m3·mol-1ChemAxon
Polarizability43.95 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Hun Wang, Jun Park, Min Kwon, Ji Shim, Bong Lee, Hong Jeon, “Controlled release formulation of tamsulosin hydrochloride and preparation process thereof.” U.S. Patent US20050100606, issued May 12, 2005.

US20050100606
General References
  1. Dunn CJ, Matheson A, Faulds DM: Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002;19(2):135-61. [PubMed:11950378 ]
  2. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ: Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs. 2002;62(1):135-67. [PubMed:11790159 ]
  3. Wilt TJ, Mac Donald R, Rutks I: Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2003;(1):CD002081. [PubMed:12535426 ]
External Links
ATC CodesG04CA02G04CA52G04CA53
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (248 KB)
MSDSDownload (20.3 KB)
Interactions
Drug Interactions
Drug
AlfuzosinAlfuzosin may increase the antihypertensive activities of Tamsulosin.
AmlodipineTamsulosin may increase the hypotensive activities of Amlodipine.
AmrinoneTamsulosin may increase the hypotensive activities of Amrinone.
AprepitantThe serum concentration of Tamsulosin can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Tamsulosin can be increased when it is combined with Atazanavir.
BepridilTamsulosin may increase the hypotensive activities of Bepridil.
BexaroteneThe serum concentration of Tamsulosin can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of Tamsulosin can be increased when it is combined with Boceprevir.
BosentanThe serum concentration of Tamsulosin can be decreased when it is combined with Bosentan.
BupropionThe serum concentration of Tamsulosin can be increased when it is combined with Bupropion.
CeritinibThe serum concentration of Tamsulosin can be increased when it is combined with Ceritinib.
CimetidineThe serum concentration of Tamsulosin can be increased when it is combined with Cimetidine.
CinacalcetThe serum concentration of Tamsulosin can be increased when it is combined with Cinacalcet.
ClarithromycinThe serum concentration of Tamsulosin can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Tamsulosin can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of Tamsulosin can be increased when it is combined with Cocaine.
ConivaptanThe serum concentration of Tamsulosin can be increased when it is combined with Conivaptan.
DabrafenibThe serum concentration of Tamsulosin can be decreased when it is combined with Dabrafenib.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Tamsulosin.
DarunavirThe serum concentration of Tamsulosin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Tamsulosin can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Tamsulosin can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Tamsulosin can be increased when it is combined with Delavirdine.
DipivefrinTamsulosin may decrease the vasoconstricting activities of Dipivefrin.
FelodipineTamsulosin may increase the hypotensive activities of Felodipine.
FluconazoleThe metabolism of Tamsulosin can be decreased when combined with Fluconazole.
FlunarizineTamsulosin may increase the hypotensive activities of Flunarizine.
FluoxetineThe serum concentration of Tamsulosin can be increased when it is combined with Fluoxetine.
FosaprepitantThe serum concentration of Tamsulosin can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Tamsulosin can be increased when it is combined with Fusidic Acid.
GabapentinTamsulosin may increase the hypotensive activities of Gabapentin.
IdelalisibThe serum concentration of Tamsulosin can be increased when it is combined with Idelalisib.
IndinavirThe serum concentration of Tamsulosin can be increased when it is combined with Indinavir.
IsradipineTamsulosin may increase the hypotensive activities of Isradipine.
ItraconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Tamsulosin can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Ketoconazole.
LamotrigineTamsulosin may increase the hypotensive activities of Lamotrigine.
LercanidipineTamsulosin may increase the hypotensive activities of Lercanidipine.
LuliconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Luliconazole.
Magnesium SulfateTamsulosin may increase the hypotensive activities of Magnesium Sulfate.
MethotrimeprazineThe serum concentration of Tamsulosin can be increased when it is combined with Methotrimeprazine.
MidodrineTamsulosin may decrease the vasoconstricting activities of Midodrine.
MifepristoneThe serum concentration of Tamsulosin can be increased when it is combined with Mifepristone.
MitotaneThe serum concentration of Tamsulosin can be decreased when it is combined with Mitotane.
NadololNadolol may increase the orthostatic hypotensive activities of Tamsulosin.
NefazodoneThe serum concentration of Tamsulosin can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Tamsulosin can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Tamsulosin can be increased when it is combined with Netupitant.
NicardipineTamsulosin may increase the hypotensive activities of Nicardipine.
NimodipineTamsulosin may increase the hypotensive activities of Nimodipine.
NisoldipineTamsulosin may increase the hypotensive activities of Nisoldipine.
NitrendipineTamsulosin may increase the hypotensive activities of Nitrendipine.
PalbociclibThe serum concentration of Tamsulosin can be increased when it is combined with Palbociclib.
ParoxetineThe serum concentration of Tamsulosin can be increased when it is combined with Paroxetine.
PerhexilineTamsulosin may increase the hypotensive activities of Perhexiline.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Tamsulosin.
PhenytoinThe metabolism of Tamsulosin can be increased when combined with Phenytoin.
PosaconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Posaconazole.
PrazosinPrazosin may increase the antihypertensive activities of Tamsulosin.
PrenylamineTamsulosin may increase the hypotensive activities of Prenylamine.
QuinidineThe serum concentration of Tamsulosin can be increased when it is combined with Quinidine.
RisedronateTamsulosin may increase the hypotensive activities of Risedronate.
RitonavirThe serum concentration of Tamsulosin can be increased when it is combined with Ritonavir.
SaquinavirThe serum concentration of Tamsulosin can be increased when it is combined with Saquinavir.
SiltuximabThe serum concentration of Tamsulosin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Tamsulosin can be increased when it is combined with Simeprevir.
St. John's WortThe serum concentration of Tamsulosin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Tamsulosin can be increased when it is combined with Stiripentol.
TadalafilTadalafil may increase the hypotensive activities of Tamsulosin.
TelaprevirThe serum concentration of Tamsulosin can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Tamsulosin can be increased when it is combined with Telithromycin.
TerbinafineThe serum concentration of Tamsulosin can be increased when it is combined with Terbinafine.
ThioridazineThe serum concentration of Tamsulosin can be increased when it is combined with Thioridazine.
TipranavirThe serum concentration of Tamsulosin can be increased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Tamsulosin can be decreased when it is combined with Tocilizumab.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Tamsulosin.
VardenafilVardenafil may increase the hypotensive activities of Tamsulosin.
VerapamilTamsulosin may increase the hypotensive activities of Verapamil.
VoriconazoleThe serum concentration of Tamsulosin can be increased when it is combined with Voriconazole.
Food Interactions
  • Take 30 minutes after a meal (always after the same meal). Taking the drug with food minimizes plasma levels variations.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Abrams P, Speakman M, Stott M, Arkell D, Pocock R: A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 1997 Oct;80(4):587-96. [PubMed:9352698 ]
  3. Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304. [PubMed:10503165 ]
  4. Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997 Oct;80(4):606-11. [PubMed:9352700 ]
  5. Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):155-67. [PubMed:8647141 ]
  6. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):145-54. [PubMed:8647140 ]
  7. Chen Y, Li H, Dong Q, Wang KJ: Blockade of alpha 1A-adrenoceptor: a novel possible strategy for male contraception. Med Hypotheses. 2009 Aug;73(2):140-1. doi: 10.1016/j.mehy.2009.02.022. Epub 2009 May 8. [PubMed:19427736 ]
  8. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchyiuma T, Korstanje C, Chapple CR: The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol. 1997 Jan;120(2):231-8. [PubMed:9117115 ]
  3. Lowe FC: Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia. Rev Urol. 2005;7 Suppl 4:S13-21. [PubMed:16986050 ]
  4. Tomiyama Y, Tatemichi S, Tadachi M, Kobayashi S, Hayashi M, Kobayashi M, Yamazaki Y, Shibata N: [Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:225-30. [PubMed:16518087 ]
  5. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41. [PubMed:12270758 ]
  6. Taguchi K, Saitoh M, Sato S, Asano M, Michel MC: Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther. 1997 Jan;280(1):1-5. [PubMed:8996174 ]
  7. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41. [PubMed:12270758 ]
  2. Michel MC, Hanft G, Gross G: Functional studies on alpha 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol. 1994 Feb;111(2):539-46. [PubMed:7911719 ]
  3. Taguchi K, Saitoh M, Sato S, Asano M, Michel MC: Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther. 1997 Jan;280(1):1-5. [PubMed:8996174 ]
  4. Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA: Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Prostate. 1997 Sep 15;33(1):55-9. [PubMed:9294627 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother. 2004 Jan;5(1):151-60. [PubMed:14680444 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Matsushima H, Watanabe T, Higuchi S: Effect of alpha(1)-acid glycoprotein on the pharmacokinetics of tamsulosin in rats treated with turpentine oil. J Pharm Sci. 2000 Apr;89(4):490-8. [PubMed:10737910 ]
  2. Hanada K, Tochikura N, Ogata H: Selective binding of tamsulosin to genetic variants of human alpha1-acid glycoprotein. Biol Pharm Bull. 2007 Aug;30(8):1593-5. [PubMed:17666829 ]
  3. Koiso K, Akaza H, Kikuchi K, Aoyagi K, Ohba S, Miyazaki M, Ito M, Sueyoshi T, Matsushima H, Kamimura H, Watanabe T, Higuchi S: Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein. J Clin Pharmacol. 1996 Nov;36(11):1029-38. [PubMed:8973992 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 26, 2016 02:10